Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
androgen deprivation therapy + docetaxel
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous (for Docetaxel), Subcutaneous (for Some Forms Of Adt, E.g., GnRH Agonist/antagonist), Intramuscular (for Some Forms Of Adt), Oral (for Antiandrogens As Part Of Adt)
01
Overview
**Androgen deprivation therapy + docetaxel** is a combination regimen primarily used for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). Androgen deprivation therapy (ADT) involves medical or surgical methods to reduce androgen levels or block the action of androgens, thereby depriving prostate cancer cells of growth signals. Docetaxel is a taxane-class chemotherapeutic agent that inhibits microtubule disassembly, leading to apoptotic cell death. The combination of ADT and docetaxel provides a dual mechanism: suppression of androgen-driven proliferation and direct cytotoxicity to cancer cells, leading to improved progression-free and overall survival in eligible patients.
- Other names
- ADT + docetaxelchemohormonal therapy for prostate cancer
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)AR (Adrenergic receptors)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on androgen deprivation therapy + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on androgen deprivation therapy + docetaxel.